Biomaterials for drug delivery
The recent advances in the synthesis and characterisations of novel biomaterials have significantly influenced the traditional approaches in the treatment of diseases and replaced them with the more efficacious therapies. The design and fabrication of novel drug delivery systems (DDSs) using smart biomaterials has also led to considerable advancements in tissue engineering and regenerative medicine through developing interdisciplinary collaborations among chemists, biologists, clinicians, and engineers. Here at Keele University, our team has substantial expertise in the synthesis of smart and responsive biomaterials and designing and fabricating a multitude of micro/nanoparticulate devices and implants that can be utilised in the diagnosis of the diseases (e.g. cancers) and targeted delivery of therapeutic agents at the site of action. We have also synthesised polymeric (PCL, PLGA, PEI) nanoparticles for the delivery of multiple drugs and bioactive agents (e.g. DNA, miRNA, etc.) in ‘programmed’ and ‘on-demand’ approaches.
The co-delivery of doxorubicin and p53-pDNA using amphiphilic copolymer with bio-cleavable disulfide linkage